TOP2A and non-small cell lung carcinoma: Log-rank test indicated that male sex (P = 0.036, Figure 2A), earlier pathological TNM stage (P = 0.001, Figure 2B) and pathological N stage (P < 0.001), non-adenocarcinoma (P = 0.004, Figure 2C) and high TopIIα expression (P = 0.012, Figure 2D) predicted better DFS in postoperative NSCLC patients who received adjuvant chemotherapy.